ALK and non-small cell lung carcinoma: However, considering the link between TP53 mutations in NSCLC and diminished responsiveness to EGFR, ALK, and ROS1 targeted therapy in diverse studies, the discourse delved into the influence of TP53 mutations on treatment resistance.